In an exclusive interview with India Pharma Outlook, JaideepGogtay, Global Chief Medical Officer at Cipla, discusses how pharmaceutical companies in India are adjusting their R&D strategies to address antimicrobial resistance (AMR). The discussion...

CDSCO, in partnership with IDMA and the Drugs Control Administration of Dadra & Nagar Haveli and Daman & Diu, held a "One Day Workshop on Quality Culture" during which Dr. S. Eswara Reddy, Joint Drugs Controller (India), CDSCO, shared his views on...

First it needs to be understood what is active TB and what is TB infection before going into the advancements in the diagnostic methodologies. India has a huge number of registered active TB cases which usually affects the lungs and can also affect o

The biggest challenge in drug discovery today is the time taken. The number of new drugs entering the market compared to the number of drugs required is very less. Moreover, for the phase 2 clinical trials, the failure rate is over 90% percent which

There is a new-found dynamism in the Indian medical technology market.

How technology puts pharmaceuticals industry in a strong position of offering improved healthcare by enhancing competitiveness and improving patient compliance by a huge margin

As of today, around 70 percent of critical Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs)are imported. The PLlscheme is meant for promotion of domestic manufacturing of critical KSMs, Drug intermediates and APIs in India.

Product diversifications happen to fulfil evolving customer and market needs and to capitalise on the emerging market opportunities.

Unani, after the Greeks and the Arabs, is only surviving in India. It is flourishing and developing in India, and that speaks volumes for our society and our culture as such, because the Indian culture has